- Home
- GNPX vs YGMZ Comparison
GNPX vs YGMZ Comparison
Compare GNPX & YGMZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNPX
- YGMZ
- Stock Information
- Founded
- GNPX 2009
- YGMZ 2002
- Country
- GNPX United States
- YGMZ China
- Employees
- GNPX N/A
- YGMZ N/A
- Industry
- GNPX Biotechnology: Pharmaceutical Preparations
- YGMZ Transportation Services
- Sector
- GNPX Health Care
- YGMZ Consumer Discretionary
- Exchange
- GNPX Nasdaq
- YGMZ Nasdaq
- Market Cap
- GNPX 10.8M
- YGMZ 10.7M
- IPO Year
- GNPX 2018
- YGMZ 2020
- Fundamental
- Price
- GNPX $5.85
- YGMZ $0.12
- Analyst Decision
- GNPX
- YGMZ
- Analyst Count
- GNPX 0
- YGMZ 0
- Target Price
- GNPX N/A
- YGMZ N/A
- AVG Volume (30 Days)
- GNPX 1.8M
- YGMZ 10.1M
- Earning Date
- GNPX 11-14-2025
- YGMZ 01-01-0001
- Dividend Yield
- GNPX N/A
- YGMZ N/A
- EPS Growth
- GNPX N/A
- YGMZ N/A
- EPS
- GNPX N/A
- YGMZ N/A
- Revenue
- GNPX N/A
- YGMZ $40,429,750.00
- Revenue This Year
- GNPX N/A
- YGMZ N/A
- Revenue Next Year
- GNPX N/A
- YGMZ N/A
- P/E Ratio
- GNPX N/A
- YGMZ N/A
- Revenue Growth
- GNPX N/A
- YGMZ N/A
- 52 Week Low
- GNPX $4.60
- YGMZ $0.11
- 52 Week High
- GNPX $117.50
- YGMZ $1.54
- Technical
- Relative Strength Index (RSI)
- GNPX 57.62
- YGMZ 29.26
- Support Level
- GNPX $7.71
- YGMZ $0.11
- Resistance Level
- GNPX $9.89
- YGMZ $0.15
- Average True Range (ATR)
- GNPX 1.35
- YGMZ 0.04
- MACD
- GNPX -0.24
- YGMZ -0.01
- Stochastic Oscillator
- GNPX 43.95
- YGMZ 1.61
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
About YGMZ MingZhu Logistics Holdings Limited
MingZhu Logistics Holdings Ltd is a Holding company. Its business activities include trucking services and car owner services. The segments of the company are the trucking business, car owner services business, and liquor distribution business.